Program
arexvy
Also written as “RSVPreF3 OA investigational vaccine”, “RSVPreF3 OA vaccine” and “RSVPreF3 OA Investigational Vaccine”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 183 open or running | phase 3since Jan 27, 2021 | Jan 11, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jan 11, 2019.
- Sep 12, 2019Phase 1 study in Respiratory Syncytial Virus InfectionsNCT04090658 · 40 enrolled · Japan
- Dec 1, 2020Phase 2 study in Respiratory Syncytial Virus InfectionsNCT04657198 · 126 enrolled · United States, Belgium
- Jan 27, 2021Phase 3 study in Respiratory Syncytial Virus InfectionsNCT04732871 · 1,720 enrolled · United States, Finland, Germany and more
- Apr 8, 20212 phase 3 studies in Respiratory Syncytial Virus InfectionsNCT04841577, NCT04886596
- Sep 17, 2021Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05059301 · 770 enrolled · United States, Canada, Sweden
- Sep 26, 2022Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05559476 · 1,029 enrolled · United States
- Oct 3, 20222 phase 3 studies in Respiratory Syncytial Virus InfectionsNCT05568797, NCT05590403
- Jun 16, 2023Phase 2 study in Respiratory Syncytial Virus InfectionsNCT05921903 · 386 enrolled · United States, Australia, Canada and more
- Jul 21, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsNCT05966090 · 530 enrolled · United States, Canada
- Apr 16, 20242 phase 3 studies in Respiratory Syncytial Virus InfectionsNCT06374394, NCT06389487
- Jul 30, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06534892 · 10,212 enrolled · United States, Australia, Belgium and more
- Aug 9, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06551181 · 2,620 enrolled · China, Finland, Japan and more
- Sep 24, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06614725 · 751 enrolled · India
- Oct 21, 2025Phase 3 study in Respiratory Syncytial Virus InfectionsNCT07220109 · 750 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A respiratory syncytial virus (RSV) vaccine, that can potentially be used for the active immunization and prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older”NCIt, by rule
“Fusion glycoprotein F0 vaccine antigen”ChEMBL 37, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07220109Respiratory Syncytial Virus Infections · China | 3 | Active, not recruiting | Jul 20, 2026 | 750 |
| NCT06614725Respiratory Syncytial Virus Infections · India | 3 | Completed | Jun 3, 2025 | 751 |
| NCT06551181Respiratory Syncytial Virus Infections · China, Finland, Japan and more | 3 | Completed | Apr 24, 2025 | 2,620 |
| NCT06534892Respiratory Syncytial Virus Infections · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 30, 2026 | 10,212 |
| NCT06389487Respiratory Syncytial Virus Infections · United States, Australia, Canada and more | 3 | Completed | Jul 29, 2024 | 1,459 |
| NCT06374394Respiratory Syncytial Virus Infections · United States, Belgium, Netherlands and more | 3 | Completed | Nov 1, 2024 | 841 |
| NCT05966090Respiratory Syncytial Virus Infections · United States, Canada | 3 | Completed | Feb 19, 2024 | 530 |
| NCT05921903Respiratory Syncytial Virus Infections · United States, Australia, Canada and more | 2 | Completed | Jun 25, 2024 | 386 |
| NCT05590403Respiratory Syncytial Virus Infections | 3 | Completed | Mar 13, 2023 | 1,544 |
| NCT05568797Respiratory Syncytial Virus Infections · Belgium, Finland, France and more | 3 | Completed | Feb 17, 2023 | 1,045 |
| NCT05559476Respiratory Syncytial Virus Infections · United States | 3 | Completed | Mar 7, 2023 | 1,029 |
| NCT05059301Respiratory Syncytial Virus Infections · United States, Canada, Sweden | 3 | Completed | Jan 24, 2022 | 770 |
| NCT04886596Respiratory Syncytial Virus Infections · United States, Australia, Belgium and more | 3 | Completed | Apr 11, 2022 | 26,675 |
| NCT04841577Respiratory Syncytial Virus Infections · New Zealand, Panama, South Africa | 3 | Completed | Sep 22, 2021 | 976 |
| NCT04732871Respiratory Syncytial Virus Infections · United States, Finland, Germany and more | 3 | Active, not recruiting | Jun 6, 2022 | 1,720 |
| NCT04657198Respiratory Syncytial Virus Infections · United States, Belgium | 2 | Completed | Jun 3, 2021 | 126 |
| NCT04090658Respiratory Syncytial Virus Infections · Japan | 1 | Completed | Jan 10, 2020 | 40 |
| NCT03814590Respiratory Syncytial Virus Infections · United States, Belgium | 2 | Completed | Dec 12, 2019 | 1,053 |
How it is read
Names in the registry
- “RSVPreF3 OA investigational vaccine”, 10 entries
- “RSVPreF3 OA vaccine”, 4 entries
- “RSVPreF3 OA Investigational Vaccine”, 1 entry
- “RSV Vaccine (GSK3844766A) unadjuvanted low dose”, 1 entry
- “RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E”, 1 entry
Codes read as this program: GSK3844766A.
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 18 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.